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inadequate folic Acid intake 
Among Women taking Antiepileptic 
Drugs During pregnancy in Japan: A 
cross-Sectional Study
Yasuko ikeda-Sakai1, Yoshiyuki Saito1, taku obara2,3,4, Mikako Goto5, tami Sengoku1, 
Yoshimitsu takahashi  1, Hiromi Hamada6, takeo nakayama1 & Atsuko Murashima7,8
this study aimed to assess characteristics of pregnant women taking antiepileptic drugs with 
inadequate folic acid intake. this cross-sectional study examined pregnant women taking antiepileptic 
drugs who were registered in the Japanese Drug information institute in pregnancy (JDiip) database 
between October 2005 and December 2016. Participants were classified into two groups according 
to when they started folic acid supplementation (before pregnancy: ‘adequate’, after pregnancy or 
never: ‘inadequate’). Logistic regression analysis was performed to investigate factors associated with 
inadequate folic acid intake. Of 12,794 registrants, 468 pregnant women were taking antiepileptics 
during the first trimester. Of these, we analysed data from 456 women who had no missing data. As 
a result, inadequate folic acid intake was noted among 83.3% of them, suggesting that the current 
level of folic acid intake is insufficient overall. Younger age, smoking, alcohol drinking, multiparity, 
unplanned pregnancy, and being prescribed AeDs by paediatric or psychiatric departments were 
independent factors associated with inadequate folic acid intake. As planned pregnancy was the 
strongest factor, healthcare professionals should ensure that childbearing women taking antiepileptics 
are informed of the importance of planned pregnancy. in addition, healthcare professionals must gain 
a better understanding of folic acid intake, as the prevalence of adequate intake differed according to 
which departments prescribed antiepileptic drugs.
Perinatal use of antiepileptic drugs (AEDs) increases the risk for both congenital malformation and neurodevel-
opmental impairment in children1,2. The risk varies by type of AED and dosage. A comparison of different AEDs 
revealed that children exposed to valproate sodium had the greatest risk of malformation1, with an even higher 
risk for those whose mothers underwent AED polytherapy as opposed to monotherapy3. The presence of physical 
abnormalities in children of women with epilepsy was more dependent on the use of AEDs during pregnancy 
than epilepsy itself4. Therefore, perinatal AED use should be approached with great caution, as most women with 
epilepsy must continue AED treatment during pregnancy to ensure adequate seizure control. Notably, AEDs are 
used to treat a broader range of diseases during pregnancy aside from epilepsy, including headache, neuropathic 
pain, bipolar disorder, and other mental disorders5. Valproate sodium is the only AED with specific instructions 
to avoid use in childbearing women to the extent possible even in monotherapy in various clinical guidelines6–8, 
and the need to select AEDs with caution is stressed when used in polytherapy6,7.
Folic acid supplementation before conception reduces the incidence of neural tube defects in infants9–11. 
Preconceptional folic acid supplementation is recommended for childbearing women, as it is difficult to ensure 
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adequate folate intake solely through diet. In addition, synthetic folic acid has a higher bioavailability than the 
natural form of folate. In particular, fertile women undergoing AED treatment should take folic acid, because 
some AEDs promote folate metabolism and lower folic acid blood levels12, which may contribute to the impaired 
cognitive function in children and foetal malformation including neural tube defects. Folic acid supplementation 
has also been found to reduce the risk of autism in children exposed to AEDs during pregnancy13.
Accordingly, childbearing women undergoing AED treatment should ensure that their folic acid intake is 
adequate. Unfortunately, the current status of folic acid intake among pregnant women taking AEDs is unclear. 
The present study aimed to clarify folic acid intake among pregnant women taking AEDs and determine charac-
teristics of those for whom intake is inadequate.
Results
Setting and participants. Data were collected from women registered in the Japan Drug Information 
Institute in Pregnancy (JDIIP) database. JDIIP provides consultations and collects data on “the influence of med-
ication on pregnant women and nursing mothers/foetuses”. Of the 12,794 registrants in the JDIIP database from 
October 2005 to December 2016, 468 pregnant women were taking AEDs during the first trimester; we analysed 
data from 456 of these women who had no missing data. Twelve women were excluded as they were missing data 
for the following items: folic acid intake (n = 6), planned pregnancy (n = 5), fertility treatment (n = 5), body mass 
index (n = 1), parity (n = 1), and history of spontaneous and artificial abortion (n = 1) (Fig. 1).
participant characteristics. Maternal characteristics are shown in Table 1. Of our study population, 35.1% 
had planned pregnancies (65.8% among those with adequate folic acid intake, 34.6% among women who started 
folic acid supplementation after finding out that they were pregnant, and 24.9% among those with no folic acid 
intake). Mental and behavioural disorders (59.9%) were the most common diseases under treatment, followed by 
epilepsy (39.0%). AED treatment during the first trimester (Table 2) was undergone as monotherapy in 85.1% and 
polytherapy in 14.9%. Valproate sodium was the most frequently taken AED (49.3%). The prevalence of valproate 
sodium use among women with and without planned pregnancies was 37.5% and 55.7%, respectively. Among 
225 participants taking valproate sodium, epilepsy, mood disorders, and other diseases with neither epilepsy nor 
mood disorders were noted as the diseases under treatment by 28.9%, 44.4%, and 35.6%, respectively (Table 3).
folic acid intake. Folic acid intake included that for both supplements available over-the-counter as well as 
prescription folic acid. Among all participants, 76 (16.7%) demonstrated adequate folic acid intake before preg-
nancy, 159 (34.9%) began supplementation after pregnancy, and 221 (48.5%) did not take any (Table 1). Those 
who received folic acid prescriptions from medical institutions comprised 89 participants (19.5%). Daily doses 
of folic acid prescription ranged from 0.5 to 20 mg, with 4 mg or more in 70 participants and unclear doses in 5 
participants. For supplements available over-the-counter, the exact number of tablets taken daily was recorded 
only for 3 of 152 participants. Figure 2 shows folic acid intake according to department prescribing AEDs. Most 
participants were prescribed AEDs by the department of psychiatry (n = 154), followed by neurosurgery (n = 53), 
neurology (n = 52), and psychosomatic medicine (n = 50). 117 women left blank the department that prescribed 
AEDs (a “blank” answer meant either “unanswered” or “department other than those listed as options”). The prev-
alence of adequate folic acid intake ranged from 0 to 33.3% depending on the departments that prescribed AEDs.
characteristics of participants with inadequate folic acid intake. Multivariate analysis identified 
younger age, smoking, alcohol drinking, multiparity, unplanned pregnancy, and being prescribed AEDs by pae-
diatric or psychiatric departments as independent factors associated with inadequate folic acid intake (Table 4). 
Multicollinearity between explanatory variables was not observed as the maximum of variance inflation factor 
was 2.18.
Figure 1. Flow chart for participant screening. JDIIP, Japan Drug Information Institute in Pregnancy.
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Total
(n = 456)
Adequate intake Inadequate intake
Before pregnancy
(n = 76)
After pregnancy
(n = 159)
No intake
(n = 221)
Age, mean (SD) 31.0 (5.4) 32.8 (4.8) 30.5 (4.6) 30.7 (5.8)
Age (category), n (%)
   < 20 years 9 (2.0) 0 (0) 3 (1.9) 6 (2.7)
   21-29 years 165 (36.0) 18 (23.4) 66 (41.3) 81 (36.7)
   30-39 years 255 (56.1) 51 (67.5) 83 (52.5) 121 (54.8)
   ≥ 40 years 27 (5.9) 7 (9.1) 7 (4.4) 13 (5.9)
Body mass index, n (%)
   < 18.5 86 (18.9) 15 (19.7) 22 (13.8) 49 (22.2)
   ≥ 18.5 and < 25 304 (66.7) 53 (69.7) 114 (71.7) 137 (62.0)
   ≥ 25 66 (14.5) 8 (10.5) 23 (14.5) 35 (15.8)
Smoking, n (%) 128 (28.1) 9 (11.8) 37 (23.3) 82 (37.1)
Alcohol drinking, n (%) 174 (38.2) 17 (22.4) 67 (42.1) 90 (40.7)
Parity, n (%)
   Primiparity 357 (78.3) 67 (88.2) 121 (76.1) 169 (76.5)
   Multiparity 99 (21.7) 9 (11.8) 38 (23.9) 52 (23.5)
Spontaneous abortion, n (%) 72 (15.8) 18 (23.7) 18 (11.3) 36 (16.3)
Artificial abortion, n (%) 100 (21.9) 15 (19.7) 31 (19.5) 54 (24.4)
Fertility treatment, n (%) 26 (5.7) 12 (15.8) 12 (7.5) 2 (0.9)
Planned pregnancy, n (%) Unplanned pregnancy 160 (35.1) 50 (65.8) 55 (34.6) 55 (24.9)
Diseases under treatment, n (%)
   Epilepsy 178 (39.0) 45 (59.2) 73 (45.9) 60 (27.1)
   Headache* 18 (3.9) 1 (1.3) 10 (6.3) 7 (3.2)
   Other neurological diseases† 18 (3.9) 5 (6.6) 5 (3.1) 8 (3.6)
   Mental and behavioural disorders 273 (59.9) 35 (46.1) 87 (54.7) 151 (68.3)
   Collagen diseases 6 (1.3) 0 (0) 2 (1.3) 4 (1.8)
   Others 80 (17.5) 16 (21.1) 22 (13.8) 42 (19.0)
Table 1. Maternal characteristics. *Headache including migraine and cluster headache. †Other neurological 
diseases except epilepsy and headache.
Total
(n=456)
Planned pregnancy
(n=160)
Unplanned pregnancy
(n=296)
n (%) n (%) n (%)
Monotherapy or polytherapy
Monotherapy 388* (85.1) 137 (85.6) 251 (84.8)
Polytherapy 68 (14.9) 23 (14.4) 45 (15.2)
Type of antiepileptic drug
Valproate sodium 225 (49.3) 60 (37.5) 165 (55.7)
Lamotrigine 118 (25.9) 54 (33.8) 64 (21.6)
Carbamazepine 80 (17.5) 29 (18.1) 51 (17.2)
Zonisamide 32 (7.0) 13 (8.1) 19 (6.4)
Levetiracetam 26 (5.7) 13 (8.1) 13 (4.4)
Phenobarbital 25 (5.5) 6 (3.8) 19 (6.4)
Phenytoin 14 (3.1) 7 (4.4) 7 (2.4)
Topiramate 11 (2.4) 2 (1.3) 9 (3.0)
Gabapentin 10 (2.2) 2 (1.3) 8 (2.7)
Ethosuximide 1 (0.2) 1 (0.6) 0 (0)
Lacosamide 0 (0) 0 (0) 0 (0)
Perampanel 0 (0) 0 (0) 0 (0)
Primidone 0 (0) 0 (0) 0 (0)
Table 2. Antiepileptic drug treatment during the first trimester. *381 continued the same antiepileptic drug, 7 
switched an antiepileptic drug to a different one.
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Discussion
The present study examined folic acid intake and determined characteristics of those with inadequate folic acid 
intake among pregnant women taking AEDs, using data from the JDIIP database. Of our study population, 83.3% 
did not take folic acid before pregnancy. These women with inadequate folic acid intake were more likely to be 
younger, have a history of smoking or alcohol drinking, multiparous, prescribed AEDs by paediatric or psychiat-
ric departments, and less likely to have a planned pregnancy. The prevalence of adequate folic acid intake ranged 
from 0 to 33.3% in the various departments that had prescribed AEDs. Mental and behavioural disorders were the 
most common diseases for which AEDs were prescribed as treatment, followed by epilepsy.
Folic acid intake, including both supplemental over-the-counter and prescription folic acid, was insufficient 
among pregnant women taking AEDs. Although the prevalence of inadequate folic acid intake in the present 
study (83.3%) was lower than that of general women in a nationwide population-based cohort study in Japan 
(92.6%)14, the current state of folic acid intake should be improved given that children of pregnant women taking 
AEDs are at greater risk of developing congenital malformations than those of general childbearing women. 
Participants who started folic acid intake after pregnancy (comprising one-third of all participants) intended to 
take folic acid as well as those with adequate folic acid intake. Nonetheless, these participants did not start folic 
acid intake before finding out that they were pregnant and thus the full effect of folic acid supplementation can-
not be expected in such cases. One reason for this may be related to whether or not the pregnancy was planned 
(planned pregnancies were noted for 65.8% with adequate folic acid intake and 34.6% of those starting folic acid 
after pregnancy). Further investigation is required to identify factors to explain why some women did not take 
any folic acid.
Valproate sodium 
user
(n=225)
Non-valproate 
sodium user
(n=231)
n (%) n (%)
Epilepsy 65 (28.9) 113 (48.9)
Headache 17* (7.6) 1 (0.4)
Other neurological diseases 3† (1.3) 15 (6.5)
Mental and behavioural disorders 156 (69.3) 117 (50.7)
   Mood disorders 100 (44.4) 84 (36.4)
   No mood disorders 56‡ (24.9) 33 (14.3)
Collagen diseases 0 (0) 6 (2.6)
Others 44§ (19.6) 36 (15.6)
Table 3. Diseases under treatment. *1 with epilepsy only, 1 with mood disorders only. 15 with migraine, 2 with 
cluster headache. †1 with epilepsy only, 2 with brain tumour. ‡7 with epilepsy. §5 with epilepsy only, 24 with 
mood disorders only, 1 with both epilepsy and mood disorders.
9.1 17.0
30.8
18.0
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Figure 2. Folic acid intake according to department prescribing antiepileptic drugs. The following departments 
are not shown. n = 2; Obstetrics and gynaecology. n = 1; Dentistry, Otorhinolaryngology, Rheumatology (all 
subjects had no folic acid supplementation), Headache clinic, and Anaesthesiology (all subjects had adequate 
folic acid supplementation).
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Women with planned pregnancies were more likely to have adequate folic acid intake. This was consistent with 
results from previous population-based studies15–17 and a hospital-based study18 of general pregnant women. In 
the present study, a planned pregnancy was the strongest factor associated with folic acid intake. Another study 
found a non-significant association between planned pregnancy and prescription of folic acid, but women with 
epilepsy who had planned pregnancies tended to have lower foetal exposure to AEDs through the selection of 
monotherapy and by avoiding valproate sodium use19. The present study also found a lower prevalence of val-
proate sodium use in those with planned pregnancies than in those with unplanned pregnancies (37.5% versus 
55.7%, respectively), even though the prevalence of AED polytherapy was comparable in both of these groups, at 
approximately 15%. Having a planned pregnancy may improve the mother’s behaviour, such as preconceptional 
folic acid intake and AED adjustment to allow for lower teratogenic risk. On the other hand, since unplanned 
pregnancies currently represent the majority, a system may need to be developed to guide women toward ade-
quate folic acid intake prior to attempting to get pregnant. One potential solution would be to implement manda-
tory national folic acid fortification, as is done in many other countries20, but not currently in Japan.
The prevalence of adequate folic acid intake differed by the department that prescribed AEDs. Those who 
were prescribed AEDs by paediatric or psychiatric departments were less likely to have adequate folic acid intake, 
potentially due to differences in attitudes among healthcare professionals about the benefits of preconceptional 
folic acid intake or in preparation for unexpected pregnancies. Although medical treatment policies are not solely 
dependent on guidelines, actual clinical practice in each department might differ depending on the contents of 
guidelines and recommendations. In Japan, preconceptional folic acid intake for childbearing women requiring 
AED treatment is recommended in guidelines for epilepsy6 and chronic headaches7, but is not mentioned in 
guidelines for neuropathic pain8, bipolar disorder21, or schizophrenia22. An increased awareness about folic acid 
is needed among healthcare professionals, as well as among women of childbearing age, and more information 
must be provided about folic acid supplementation in disease guidelines. Targeted healthcare professionals would 
include physicians prescribing AEDs as well as those in various other occupations, e.g., pharmacists obligated to 
refer to doctors when there is any doubt about prescriptions, nurses assisting in medical treatment, and public 
health nurses performing educational activities. Notably, interpretation of our findings about folic acid intake 
according to department prescribing AEDs should be made with caution, since approximately 25% of participants 
left blank the answer regarding the department that prescribed AEDs.
Other characteristics of inadequate folic acid intake identified in this study included younger age, multiparity, 
and a history of smoking and/or alcohol drinking. These characteristics were consistent with those identified by 
other studies of general pregnant women14–17. Younger women were less likely to have planned pregnancies17 and 
knowledge of folic acid and its benefits23, demonstrating the necessity of school health education on this subject 
as well as continuous efforts to increase the awareness of the importance of folic acid intake.
One questionnaire study revealed that pregnant women obtained information on folic acid through mass 
media (47%), the Internet (17%), healthcare providers (13%), and the maternal and child health handbook 
(11%)24. The maternal and child health handbook is a booklet given to pregnant women in Japan, contains infor-
mation on safe pregnancy, childbirth, and children’s health, and is used to record their own health conditions 
as well as growth parameters of their children. Given the popularity of the Internet and mass media to obtain 
Univariable analysis Multivariable analysis
OR [95%CI] adjusted OR [95%CI]
Age (in increments of 5 years) 0.68 [0.53-0.86] 0.61 [0.46-0.82]
Body mass index*
   < 18.5 1.00 [0.53-1.88] 0.60 [0.29-1.24]
   ≥ 25 1.53 [0.69-3.39] 1.99 [0.79-5.01]
Smoking 3.39 [1.72-7.51] 2.28 [1.01-5.16]
Alcohol drinking 2.44 [1.37-4.35] 2.04 [1.08-3.87]
Multiparity 2.31 [1.11-4.82] 3.53 [1.52-8.23]
Fertility treatment 0.20 [0.09-0.46] 0.71 [0.26-1.90]
Spontaneous abortion 0.53 [0.29-0.97] 0.77 [0.36-1.62]
Artificial abortion 1.17 [0.63-2.17] 0.83 [0.40-1.72]
Planned pregnancy 0.21 [0.13-0.36] 0.28 [0.16-0.52]
Valproate sodium use during the first trimester 1.98 [1.18-3.29] 1.09 [0.60-1.97]
Polytherapy with antiepileptic drugs 0.73 [0.38-1.40] 0.50 [0.23-1.06]
Departments that prescribed antiepileptic drugs†
   Paediatrics or psychiatry 3.15 [1.65-6.03] 3.04 [1.48-6.24]
   Blank‡ 1.48 [0.82-2.67] 1.82 [0.92-3.59]
Table 4. Odds ratio for inadequate folic acid intake by logistic regression analysis. *The reference standard 
is ≥18.5 and <25. †The reference standard is department that is neither paediatrics nor psychiatry, including 
neurosurgery, neurology, psychosomatic medicine, internal medicine, obstetrics and gynaecology, dentistry, 
otorhinolaryngology, rheumatology, headache clinic, and anaesthesiology. ‡“Blank” regarding the department 
prescribing antiepileptic drugs meant either “unanswered” or “department other than those listed as options.” 
Abbreviations: OR, odds ratio; CI, confidence interval; VPA, valproate sodium.
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this information, it may be most effective to use these resources to increase awareness about folic acid intake 
among pregnant women and those considering pregnancy. Typically, communication with maternity healthcare 
providers begins after the pregnancy is confirmed, or if pregnancy issues such as spontaneous abortion occur. In 
addition, women receive their maternal and child health handbooks only after a healthcare professional confirms 
their pregnancy. Therefore, the impact of promoting preconceptional folic acid intake by either healthcare profes-
sionals or through information in the maternal and child health handbook might be limited.
Our study also found inappropriate use of valproate sodium among pregnant women taking AEDs. Perinatal 
valproate sodium use has been reported to increase the risk of congenital malformations1 and decrease IQ scores 
in children25. Indications for valproate sodium use during pregnancy are limited to those with epilepsy or bipolar 
disorder (a type of mood disorder), and the drug should only be prescribed if all other medications are ineffective 
in treating the condition or if there are no other alternatives. However, the present study found that 35.6% of 
pregnant women taking valproate sodium reported diseases other than epilepsy or mood disorders as diseases 
under treatment. Use of valproate sodium to prevent migraines is contraindicated for pregnant women because 
the risks outweigh any benefits. On a related note, all non-pregnant women of childbearing age taking valproate 
sodium to prevent migraines should use effective birth control26. Patients with chronic pain disorders or mental 
disorders other than mood disorders should also be treated in accordance with this policy.
The present study had some limitations worth noting. First, our participants may not be representative of 
all pregnant women using AEDs, as they had taken some AEDs during pregnancy and voluntarily consulted 
the JDIIP. That said, the proportion of AED users among pregnant women is very low (0.2 to 2.0%)5,27,28, and 
the present study included more than 450 participants, providing highly valuable data. Second, for supplements 
available over-the-counter, the exact number of tablets taken daily was recorded only by 3 participants because 
supplements were not considered medication. However, we estimated their daily doses of folic acid to be approxi-
mately 0.4 mg based on records of the product names. Third, since the term “before/after pregnancy” as it applies 
to when folic acid supplementation began was not strictly defined in the self-report questionnaires, potential mis-
classification might lead to overesting the prevalence of adequate folic acid intake. The accuracy of information 
could be improved with further efforts to reduce misclassification and missing data. Fourth, we did not consider 
the effects of marital status, educational history, or income, all of which are important factors related to folic acid 
intake. Despite these limitations, we gained valuable insight on pregnant women taking AEDs to treat diseases 
other than epilepsy because we did not collect data from registries limited to patients with epilepsy.
In conclusion, folic acid intake is currently insufficient among pregnant women taking AEDs. Younger age, 
smoking, alcohol drinking, multiparity, unplanned pregnancy, and being prescribed AEDs by paediatric or psy-
chiatric departments were independent factors associated with inadequate folic acid intake. Having a planned 
pregnancy was the strongest factor associated with adequate folic acid intake, and thus healthcare professionals 
should educate women of childbearing age taking AEDs about the importance of planned pregnancy. Awareness 
among healthcare professionals including clinicians and pharmacists, among others, should also be increased, as 
the prevalence of adequate folic acid intake differed depending on which department prescribed AEDs.
Methods
Study design and setting. This is a cross-sectional study of data from the JDIIP database. The JDIIP, a 
project approved by the Ministry of Health, Labour and Welfare, was conducted by the National Center for Child 
Health and Development beginning in October 2005.
participants. Pregnant women who used AEDs during the first trimester of pregnancy and who were regis-
tered in the JDIIP database from October 2005 to December 2016 were eligible to participate. Those with missing 
data for items about maternal characteristics and folic acid intake were excluded. AEDs used by participants 
included carbamazepine, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, perampanel, pheny-
toin, phenobarbital, primidone, topiramate, valproate sodium, and zonisamide. Oxcarbazepine was not included 
since it has not been released in Japan.
Data collection. Women desiring a consultation completed a questionnaire form containing information 
on their medication use and mailed it to apply for consultation. Consultations could occur by three ways: (1) By 
telephone: a physician/pharmacist responds to common consultations about items such as cold medicine and 
analgesics; (2) A woman visits one of the 39 JDIIP outpatient clinics nationwide and a medical specialist responds 
to the consultation; or (3) A woman visits her attending physician, who then provides an explanation based on 
the response from the JDIIP.
Items in the database were maternal age, height, body weight before pregnancy, smoking status, alcohol drink-
ing, parity, medical history, fertility treatment, planned pregnancy, medication use (product name, generic name, 
date of start and discontinuation, daily dose, department that prescribed the medication), and folic acid intake 
(both prescription and supplementary over-the-counter; for the latter, product name and timing of initiation), as 
collected from the questionnaire surveys. In addition, some women agreed to return a postcard survey on neo-
natal outcomes to indicate outcomes including congenital malformation. Women who reportedly never smoked 
or who quit smoking before pregnancy (i.e., before the day the last menstrual period started) were defined as 
non-smokers and women who reported that they were still smoking or had smoked until pregnancy confirmation 
were defined as smokers. The same guidelines were used to define alcohol drinking. The definition of a planned 
pregnancy was that the woman intended her pregnancy. If there was any ambiguity in the description of the ques-
tionnaire, research coordinators either confirmed by phone, or pharmacists or doctors provided confirmation at 
the consultation.
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outcome and statistical analysis. We assessed maternal characteristics and AED treatment during the 
first trimester (from 0 weeks 0 days until 13 weeks 6 days of gestation). As maternal characteristics, we extracted 
information on age, body mass index, smoking status, alcohol drinking, parity, history of spontaneous and arti-
ficial abortion, fertility treatment, planned pregnancy, and diseases under treatment. With regard to AED treat-
ment during the first trimester, we extracted information on type of AEDs (e.g., valproate sodium), date of AED 
use, monotherapy or polytherapy, and the department that prescribed AEDs.
The outcome was prevalence of folic acid intake. We classified participants into two groups, depending on 
when folic acid intake began: those who began folic acid supplementation before pregnancy were defined as 
‘adequate’ intake, while those who started after pregnancy or who never started (no intake) were defined to have 
‘inadequate’ intake. Univariable and multivariable logistic regression analyses were performed to calculate the 
odds ratio and the 95% confidence interval of the association between maternal characteristics as explanatory 
variables and inadequate intake of folic acid as the outcome variable. Multicollinearity among explanatory varia-
bles was confirmed by variance inflation factors. All statistical analyses were conducted with JMP Pro 13.0 (SAS 
Institute Inc., Cary, NC, USA).
ethical considerations. Researchers and other personnel could not identify individuals from analytical 
data, as the information was input by a research coordinator based on questionnaire forms and postcard surveys 
for neonatal outcomes. Data were anonymised by an information administrator in the JDIIP. Written informed 
consent regarding the construction of the JDIIP database was obtained from all subjects. For the purpose of 
the present study, the opt-out was adopted (we disclosed the information on this study and provided potential 
participants with the opportunity to refuse to participate). All procedures were conducted in accordance with 
ethical guidelines for medical and health research involving human subjects established by the Ministry of Health, 
Labour and Welfare in Japan. All study protocols were approved by the ethics committees of the National Center 
for Child Health and Development (No. 1502) and Kyoto University (No. R1244-1).
Data Availability
Datasets generated during the current study are not publicly available due to a lack of agreement from partici-
pants and lack of approval from the ethics committees regarding data provision to third parties. However, the 
datasets are available from the corresponding author on reasonable request for collaborative research and with 
permission from the National Center for Child Health and Development.
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